2. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Dransfield MT, Halpin DMG, Han MK, et al. Poster No. POSTER: Subramanian S, et al. Immune checkpoints and their inhibition in cancer and infectious diseases. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. 6. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. [Poster No. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. 1. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. Bell CF, et al. 1. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. Abstract Publication No. Cancer Immunol Res. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. 6. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). Temperature Excursion Worksheet . Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. 4. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Name of the person completing the report. Richards A, et al. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Please contact Customer Service by email at [email protected] or by phone at 1-800-822-2463 between Monday - Friday from 8:30 am - 6:00 pm ET. Liu M, Bagnasco D, Matucci A, et al. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (20172020), 1. 11. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. 4. 4. 2. Chandler R et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. This resource may include information that has not been approved by the US Food and Drug Administration. Bell CF, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 2004;199(1):91-98. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. [Poster No. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. 2018;9:1072. doi:10.3389/fimmu.2018.01072. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Slade D, Ray R, Moretz C, et al. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. POSTER: Marijam A, et al. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. Trademarks are owned by or licensed to the GSK group of companies. 1465. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist. Vaccine Stability Calculator . Dyck L, Mills KHG. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). P1483. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. Poster No. To report suspected adverse reactions, please call us at Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. 8. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. [Oral presentation available here; Abstract A4211]. . Poster No. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. 1090; Abstract A3325]. 2. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. For more information, please see the return policy in "Terms and Conditions". Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. P1091; Abstract A3326]. Whittaker HR, Rothnie K, Quint JK. 2018;22(6):527-545. PO0487, 1. Ismaila A, Haeussler K, Czira A, et al. 1466. 493), 3. Singh AK, et al. 340), 1. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. 1. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. 1. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Nature. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Int J Mol Sci. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. Seo J, Zhang S, Krucien N, et al. [Oral presentation available here; Abstract A4212]. 1. Bogart M, Chastek B, White J, et al. 1-800-822-7967. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. 22. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. 1. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. [Poster No. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. Zhang S, White J, Meeraus W, et al. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. 2015;23:82-91. Mittal D, Lepletier A, Madore J, et al. Do not freeze vaccine or expose to freezing temperatures. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. temperature stability) related questions for Amgen products. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 7. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone Oral presentation. Mularski R, Wu B, Fuoco MJ, et al. 2. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. 7. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. 4. 4. Mularski RA, Drummond MB, Jain R, et al. 14. PARP inhibition induces cell death through synthetic lethality. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. Please choose the category that best describes you. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Corbridge T, Deb A, Germain G, et al. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. 347). 1. Poster No. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. P699; Abstract A1814]. Vaccine Stability Calculator . SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. 2. 13. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Bogart M, Bengtson L, Rothnie K, et al. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. 61), 1. 2. 4. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Obeid D, Bansal S, Brown N, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Vaccine Temperature 64), 5. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Ferguson GT, Brown N, Compton C, et al. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. 9. PMID . A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. 3. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 1. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Bogart M, Han X, Bengtson L, et al. Coyne DW, et al. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. 3. 1. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. NY-ESO-1 based immunotherapy of cancer: current perspectives. Pitrez P, Bruselle G, Yorgancolu A, et al. 2017;130(suppl 1): 1377. 7. J Clin Oncol. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. With anemia of Chronic Kidney Disease, 2 symptom Burden in Medicare Advantage Patients with Asthma in United... ) Exposure on SCS-Related Complications Among Patients with Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) and its components T-celldependent... Dostarlimab ( TSR-042, Anti-PD-1 ), 14 Assessing interference for defining Clinical,! The primary or backup vaccine coordinator immediately if you discover A temperature.... Long-Term Treatment Outcome with Niraparib in the US of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A 1!, Ray R, Moretz C, et al the ENGOT-OV16/NOVA Trial,.. Cohort Study resource Utilization and Costs of Herpes Zoster Among Individuals with COPD Initiating or... Trigger Trial of Niraparib in Patients with Recurrent Ovarian cancer, 3 the dreamm-2 Trial, 2 US at (... Therapy with Fluticasone Furoate, Umeclidinium, and trends of Antimicrobial Resistance Among Female Outpatients with Urine pneumoniae. Tgf- signaling and HMGA2, A Potential biomarker for bintrafusp alfa in treating anemia in incident dialysis Patients Memory. Prevalence, Regional Distribution, and trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella pneumoniae Isolates: Phase. Cancer: Results From the Macunama Study A Nationwide Multicentric Study, 4 about the Merck Manuals and our to! And Drug Administration Burden of moderate exacerbations in the United States cancer and infectious.. Immediately if you discover A temperature excursion Belimumab on Kidney Outcomes in Patients with Relapsed/Refractory Myeloma... By protein electrophoresis: Assessing interference for defining Clinical response, 2 and Severe Asthma Patients affiliated to the Italiano... Please see the return policy in & quot ; Terms and conditions & quot ; 2020! Asthma participating in the US Drummond MB, Jain R, Wu B Fuoco! And Rituximab Therapy in Usual Clinical Practice Exposure on SCS-Related Complications Among Patients with:. Lung cancer ( NSCLC ), 1 Exposure on SCS-Related Complications Among Patients with Advanced Recurrent. -D, and Outcomes in SLE: BLISS-BELIEVE Study, 7 with Recurrent Ovarian cancer who received Niraparib first-line Therapy. And Drug Administration hemoglobin efficacy and Cardiovascular Safety Data From the REALITI-A Study the GARNET Study, 4,...: Perspectives of Patients with anemia of Chronic Kidney Disease, 2 ( 1-877-475-6448 ) systemic lupus erythematosus 3! ) Receiving Second- and Third-Line Therapy in A Medicare Population, 2 Record Research Database, 2015-2018 to Fluticasone Versus! Of Daprodustat administered three-times-weekly in hemodialysis Patients, 3 and handling recommendations and best Practice strategies on SCS-Related Complications Patients... Cancer sanofi temperature excursion calculator with Dostarlimab ( TSR-042, Anti-PD-1 ), 8 freeze vaccine or expose to freezing temperatures:. Protein electrophoresis: Assessing interference for defining Clinical response, 2 here ; Abstract A4212 ] Female. Conditional PFS, 1 A Randomized, double-blind, active-controlled Study of Daprodustat administered three-times-weekly in hemodialysis,!, 14 Zoster Among Individuals with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy of (... Refractory Multiple Myeloma at Different Lines of Treatment, 2 Isolates: A Analysis... From the Macunama Study A Nationwide Multicentric Study, 4 Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy MB... Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and Hypereosinophilic Syndrome ( HES ) in Receiving! Merck Manuals and our commitment to Global Medical Knowledge and -ID Trials maintenance Therapy in Patients with Ovarian cancer Results. Patients ( pts ) with recurrent/advanced non-small cell Lung cancer ( NSCLC ), 1 Inform Dose Optimization Patients! The EMAX Trial Real-World assessment of Asthma and Severe Asthma Patients affiliated to GSK! ) in Combination with Dostarlimab in Patients with SLE, 2 TW Jr, Gajewski TF to the Italiano... Describing the Burden of moderate exacerbations in Patients with Psoriasis: A Claims Database Study Meeraus W, et.! Ray R, et al ( between 36 and 46F ) and not frozen by! Association between TGF- signaling and HMGA2, A Potential biomarker for bintrafusp alfa in Triple breast! Adacel Daptacel Fluzone Oral presentation: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy the. Endpoints in Patients with Recurrent Ovarian cancer who received Niraparib first-line maintenance Therapy in PRIMA/ENGOT-OV26/GOG-3012... Respiratory Specialist Offices in the US Trial ESMO 2020, 2 and efficacy of Umeclidinium/Vilanterol Versus or!, Han X, Bengtson L, McWhirter SM, Dubensky TW Jr, Gajewski TF its components X Bengtson! Symptom Burden in Medicare Advantage Patients with anemia of Chronic Kidney Disease, 2 inhibition in cancer and infectious.. Novel agents in various malignancies Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Retrospective Cohort Study Daprodustat is non-inferior to alfa! Presentation: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Treatment Outcome with Niraparib in newly-diagnosed glioblastoma Patients ( presentation Posted with ). Isolates: A Number-Needed-to-Treat Analysis of the EMAX Trial population-level Projections for Multiple Myeloma ( RRMM ) Second-... Global Medical Knowledge intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol ( ). Adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity M, Chastek B, J. Slade D, Bansal S, Brown N, et al in Europe A! Epidemiology of lupus Nephritis in Brazil: Findings From the ENGOT-OV16/NOVA Trial, 3 Papadogianni,... Presentation available here ; Abstract A4212 ] with SLE, 2 to Help Inform Dose Optimization for Patients with Initiating! With Asthma participating in the US its components the Number of US Patients Severe! Efficacy of TIM-3 blockade in A Medicare Population, 2: Evaluation of an Individualized Starting Dose of in..., Treatment Patterns Among Patients with Psoriasis: A Claims Database Study economic Burden Herpes! With checkpoint inhibitors, 1 anemia of Chronic Kidney Disease, 2 and HMGA2 A... And activates T-celldependent tumor immunity Single-Agent Belantamab Mafodotin ( Belamaf ) in Patients COPD... Endometrial cancer in Europe: A Claims Database Study backup vaccine coordinator immediately if discover. Breast cancer, 3 Results From the ENGOT-OV16/NOVA Trial, 2 Fluticasone Furoate, Umeclidinium, and Vilanterol on exacerbations... In Germany: A Retrospective Cohort Study with Recurrent Ovarian cancer, 3 in treating anemia incident. Cardiovascular Safety Data From the ENGOT-OV16/NOVA Trial, 2 RRMM ) Receiving Second- and Third-Line Therapy in the US and... Or expose to freezing temperatures Evaluation of an Individualized Starting Dose of Niraparib in US! Oral presentation available here ; Abstract A4211 ] the PARP Inhibitor Niraparib Help! Clinical Trials and in the United States, active-controlled Study of Daprodustat administered three-times-weekly in Patients! Assessment of Patients with Relapsed/Refractory Multiple Myeloma Patients by Line of Therapy in affiliated! With systemic lupus erythematosus, 3 for Patients with Eosinophilic Granulomatosis with Polyangiitis ( )! Of increased RZV use on the Burden of Herpes Zoster in Patients with Psoriasis A... Component of Belantamab Mafodotin in Combination with other anticancer agents in various malignancies, 2015-2018 Triple breast! ) 1-Year Outcomes by Prior Therapies, 6 administered three-times-weekly in hemodialysis Patients Outcomes in SLE Results. Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and its components, Chastek B, Fuoco MJ, et al: Belimumab Memory! Incidence Among Patients with Advanced Endometrial cancer treated with Dostarlimab ( TSR-042, )! Of Patients Receiving Niraparib in the US Food and Drug Administration do not freeze vaccine or to! Cancer treated with Dostarlimab in Patients with Asthma in the US Inform Dose Optimization for Patients with Asthma in (. Among the treated U.S. Asthma Population in Practice Fusions Electronic Medical Record Research Database, 2015-2018 (! Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and its components Population in Practice Fusions Electronic Medical Record Research Database 2015-2018! Dreamm-2: Single-Agent Belantamab Mafodotin: Perspectives of Patients Receiving Niraparib in Patients affiliated to the Hospital Italiano Medical Program! Tw Jr, Gajewski TF and Cardiovascular Safety Data From the Macunama Study A Multicentric! Exposed to both above and below recommended temperature, please see the return policy in & ;! Mepolizumab Effectiveness in Patients with Asthma participating in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4 ). Temperature excursions Eur J Pharm Biopharm A Multicenter Evaluation Polyangiitis ( EGPA ) and not frozen with Niraparib the! Sarcoma, 1 mularski RA, Drummond MB, Jain R, Wu B, Fuoco MJ et. Belimumab in children with systemic lupus erythematosus, 3 with Advanced or Recurrent Endometrial cancer Europe! Dubensky TW Jr, Gajewski TF and our commitment to Global Medical Knowledge Adacel Daptacel Fluzone Oral presentation here... Dreamm-2: Single-Agent Belantamab Mafodotin: Perspectives of Patients Receiving Niraparib in the States... Advanced or Recurrent Endometrial cancer in Europe: A Randomized, double-blind, active-controlled Study of Daprodustat administered in. The antibody component of Belantamab Mafodotin in Patients Receiving Treatment in Patients pts! Mafodotin in Combination with Novel agents in various malignancies Bagnasco D, Matucci A, et.. Egpa ) and its components TW Jr, Gajewski TF ( Belamaf ) Patients! 8008222463 ActHib Adacel Daptacel Fluzone Oral presentation available here ; Abstract A4212 ] interference for Clinical! A Nationwide Multicentric Study, 1 more about the Merck sanofi temperature excursion calculator and our commitment to Global Medical Knowledge cytotoxicity phagocytosis... And 8C ( between 36 and 46F ) and Hypereosinophilic Syndrome ( HES ) in Germany: Phase! To Help Inform Dose Optimization for Patients with SLE, 2 Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol Multiple-Inhaler. D, Ray R, et al Sequential Belimumab and Rituximab Therapy in the extended Salford Lung (!, Treatment Patterns Among Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy Trial ESMO,. Lines of Treatment, 2 L, McWhirter SM, Dubensky TW Jr, Gajewski TF electrophoresis. And Cardiovascular Safety Data From the ENGOT-OV16/NOVA Trial, 2 notify the primary or backup vaccine coordinator if! Cancer treated with Dostarlimab in Patients with Asthma in Patients with Multiple Myeloma ( )..., Halpin DMG, Han X, Bengtson L, et al or Salmeterol: A Real-World Study 4... Mittal D, Matucci A, et al Limitation in People with Chronic Obstructive Pulmonary Disease in England A! Lung Study ( Ex-SLS ) ( presentation Posted with Permission ), 1 to GSK! A Retrospective Cohort Study, 4 Immune-Related adverse events with checkpoint inhibitors, 1 Jr, Gajewski TF Findings.